The Administration’s recent proposal on drug prices rightly recognizes that Americans are getting ripped off by paying higher drug prices than anyone in the world, and Big Pharma’s response is to blame others in the supply chain. Yet the simple fact is: Big Pharma sets drug prices, hikes drug prices, and blocks more affordable drugs from competing in the market. Anti-competitive practices enable big drug companies to maintain monopolies and keep prices too high, a fact the Administration recently addressed.
The sticker price, set solely by drug companies, decides the starting point for all pharmacy benefit manager (PBM) and drug company negotiations. Lower sticker prices mean patients and plan sponsors will pay less, and PBMs support lower drug prices for all prescription drugs.

In a recent op-ed published in InsideSources’ D.C. Journal, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), makes it clear that the strongest path to lower prescription drug costs starts with pharmaceutical companies lowering their list prices:
“There is a basic understanding that drug costs are too high for some patients. How to lower drug costs is equally basic: the drug companies that set the prices should lower those prices.”
Read the Full Op-Ed Here
Scott emphasizes that while PBMs are working every day to lower costs and increase access for patients, drug companies continue to raise their sticker prices at will to increase their own profits. Despite ongoing, well-funded efforts by Big Pharma to shift the debate away from their own pricing practices, the facts remain:
“PBMs don’t set drug prices and certainly are not forcing drug companies to set or keep high prices. Drug companies set the price, decide when to increase the price, block competition to keep the price high, and spend billions of dollars in advertising to promote high-priced products to consumers.”
The work of PBMs is undermined when pharmaceutical companies maintain list prices that are on average 422 percent higher in the U.S. than in other countries. Scott points out:
“Drug companies have made it their mission to deflect attention away from their sticker prices and the affordability challenge that they have created, using heavily funded advocacy campaigns to confuse the debate in Washington and state legislatures. They’ve turned policymakers’ attention largely away from their price tags and to the one industry that is a check on their pricing power: PBMs.”
The message to policymakers is clear: prescription affordability cannot be solved without lowering the list prices that drug companies alone control:
“The problem of high prescription drug prices in our country has always stemmed from the list price that’s set by drug companies, and without addressing the list price, prescription drug affordability will remain a challenge.
“That’s why PBMs and the American people are calling on drug companies to do one thing: Lower the List Price. Will they answer the call?”
Read more about Lowering the List Price HERE and learn why the price is the problem HERE.
###
###
